Variable interindividual responses to antiplatelet therapies - Do they exist, can we measure them, and are they clinically relevant? Insights from the GOLD (AU - Assessing Ultegra) trial

HeartDrug

Volumn 1, Issue 1, 2001, Pages 35-43

  Van De Graaff, Eric ^a   Steinhubl, Steven R ^a  

^a WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

Aspirin; Clopidogrel; Glycoprotein IIb IIIa inhibitors; Platelet(s); Ticlopidine

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; TICLOPIDINE; TIROFIBAN;

CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; EMBOLISM; HEART INFARCTION; HUMAN; MEDICAL RESEARCH; PRIORITY JOURNAL; REVIEW; STROKE;

EID: 0035743342     PISSN: 14229528     EISSN: None     Source Type: Journal    
DOI: 10.1159/000022709     Document Type: Review

References (61)

1. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
2. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
3. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients
4. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke
5. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
6. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
7. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
8. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
9. Inhibition by cyclo-oxygenase inhibitors of interleukin-6 production by human peripheral blood mononuclear cells
10. LNMMA in brain microcirculation of mice is inhibited by blockade of cyclooxygenase and by superoxide dismutase
11. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes
12. Individual variation in the effects of ASA on platelet function: Implications for the use of ASA clinically
13. Aggregation of blood platelets by adenosine diphosphate and its reversal
14. Aspirin response and failure in cerebral infarction
15. The lack of augmentation by aspirin of inhibition of platelet reactivity by ticlopidine
16. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty
17. A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency
18. Two-year follow-up of aspirin responder and aspirin non-responder. A pilot study including 180 post-stroke patients
19. Aspirin resistance using flow cytometry
20. Comparison of effects of high-dose and low-dose aspirin on restenosis after femoropopliteal percutaneous transluminal angioplasty
21. A metaregression analysis of the dose-response effect of aspirin on stroke
22. Differential dose effect of aspirin in the primary prevention of myocardial infarction
23. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: A randomised controlled trial
24. Development of aspirin resistance in persons with previous ischemic stroke
25. Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy
26. Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin
27. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance
28. Aspirin and platelets: The antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis
29. Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs
30. Platelet aspirin resistance is associated with an increased platelet content of cyclooxygenase-2
31. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina
32. Differential suppression of thromboxane biosynthesis by ibuprofen and aspirin in patients with unstable angina
33. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis
34. Association of the platelet Pl(A) polymorphism of glycoprotein IIb/IIIa and the fibrinogen B beta 448 polymorphism with myocardial infarction and extent of coronary artery disease
35. Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation
36. PlA2 polymorphism and efficacy of aspirin
37. Platelet GP IIIa PlA polymorphisms display different sensitivities to agonists
38. Variable response to aspirin measured by platelet aggregation and bleeding time
39. Dose-dependent aspirin hydrolysis and platelet aggregation in patients with atherosclerosis
40. Heterogeneity of the aggregation response of human platelets to arginine vasopressin
41. Cigarette smoking-induced enhancement of platelet function: Lack of prevention by aspirin in men with coronary artery disease
42. Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia
43. Sex difference in antithrombotic effect of aspirin
44. Evidence for prothrombotic effects of exercise and limited protection by aspirin
45. The prevalence of aspirin resistance in cardiac patients as measured by platelet aggregation and PFA-100
46. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase
47. Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation
48. Repeated-dose pharmacodynamics of clopidogrel in healthy subjects
49. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents
50. Attainment and maintenance of platelet inhibition by standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention
51. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention
52. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors
53. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention
54. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GPIIb/IIIa therapy
55. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade
56. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina
57. Chronic oral glycoprotein IIb/IIIa antagonism in patients with unstable coronary syndromes: Reduced antiplatelet effect in comparison to patients with stable coronary artery disease
58. Assessing the optimal level of platelet inhibition with GPIIb/IIIa inhibitors in patients undergoing coronary intervention. Rationale and design of the GOLD study
59. Rapid and simple platelet functionassay to assess glycoprotein IIb/IIIa receptor blockade
60. Rapid platelet-function assay: An automated and quantitative cartridge-based method
61. Unexpected, discordant effects of aspirin on platelet reactivity